PresentationSo with that out of the way, let me turn it over to Alkermes, CEO, Richard Pops.Because of JPMorgan's involvement with the pending transaction, we're not going to take any Q&A related to the pending deal, and I'm not going to be discussing that.Great. Welcome, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 44th Annual Healthcare Conference today with Alkermes. We're going to hear a presentation from the management team, and then we're going to go into ...

PresentationGreat. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 44th Annual Healthcare Conference today with Jazz. First, you're going to hear a presentation from the company's CEO, and then we're going to go into some Q&A. So if you're sitting in the room and you have a question, just raise your hand and we'll bring you a microphone or you can always submit them online to me, and I can read them up here.Renée GaláPresident, CEO & Director Great. ...

WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its $50 million registered direct financing at a 30% premium. The registered direct offering included the sale of 2,030,314 shares of common stock at $6.71 per share (issue price). Certain investors received pre-funded warrants to purchase up ...

PresentationWelcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is ACADIA Pharmaceuticals. And presenting on behalf of the company, we have CEO, Catherine Owen Adams. Catherine, over to you.Catherine Owen AdamsCEO & Director Thanks so much, Tess. Good morning, everybody, and thank you for joining us at the 44th Annual JPMorgan Healthcare Conference. As Tess said, my name is Cat ...

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure:I/we ...

This oncology biotech developing targeted cancer therapies saw a key insider significantly trim their direct equity stake.Garner Ebun, general counsel and corporate secretary of Erasca (ERAS +9.71%), executed an options exercise and immediate sale of 120,000 shares for a total value of $670,812 on Jan. 7, as disclosed in a recent SEC Form 4 filing.Transaction summaryMetricValueShares sold (direct)120,000Transaction value$670,800Post-transaction shares (direct common stock)25,076Post-transaction value (direc ...

PresentationKim KeldermanCEO, President & Director Thank you, Ta-Von. It's always a pleasure being here, and it's exciting to be here for the third time for myself. We have a very excited 2026 ahead of us, and I'm really looking forward going through the presentation, which will start with an overview of the company and then followed by a double click on the strategy going forward. But before I get into the data, I would like to draw your attention to our safe harbor statement, which you can find on our web ...

Coherus Oncology (NasdaqGM:CHRS) FY Conference January 13, 2026 01:30 PM ET Company ParticipantsTheresa LaVallee - Chief Scientific and Development OfficerDennis Lanfear - CEOConference Call ParticipantsBrian Cheng - Senior Biotech AnalystBrian ChengGood morning, everyone. It's still the morning. Thanks for joining us for another session at the 44th JPMorgan healthcare conference. I'm Brian Cheng. I'm one of the Senior Biotech Analysts here at the firm. On stage, we have the team from Coherus Oncology. I wi ...

PresentationGood morning, everyone. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have the CEO from Kymera Therapeutics, Nello Mainolfi. I'll now pass the mic to their CEO for a short presentation, followed by a live audience Q&A.Nello MainolfiCo-Founder, President, CEO & Director Thanks, Brian. Thanks, everybody, for joining us. Hopefully, the sound is good. Always great to be at JPMor ...

As you know, Akebia Therapeutics, Inc. ( AKBA ) makes money mainly via the commercialisation of Vafseo. It's an oral therapy approved for the treatment of anaemia due to chronic kidney disease (CKD) in adults receivingI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation f ...